Checkmate 7FL is the first prospective, phase 3, randomized trial comparing the efficacies of nivolumab (NIVO) + NACT + adjuvant ET (Arm A) and placebo + NACT/ET (Arm B) against high-risk, early-stage ER+ HER2- BC. This evidence concerns the gene ERBB2 and breast cancer.